Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CD19-22.BB.z CAR T cells |
Synonyms | |
Therapy Description |
CD19-22.BB.z CAR T cells are T-lymphocytes engineered to express a chimeric antigen receptor (CAR) that targets CD19 and CD22, which potentially induce killing of tumor cells expressing CD19 and/or CD22 and decrease tumor growth (PMID: 34312556, PMID: 29155426). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CD19-22.BB.z CAR T cells | CD19 Immune Cell Therapy 65 CD22 Immune Cell Therapy 15 | CD19-22.BB.z CAR T cells are T-lymphocytes engineered to express a chimeric antigen receptor (CAR) that targets CD19 and CD22, which potentially induce killing of tumor cells expressing CD19 and/or CD22 and decrease tumor growth (PMID: 34312556, PMID: 29155426). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05507827 | Phase I | CD19-22.BB.z CAR T cells | Myeloablative Conditioning Orca-T & Allogeneic Donor-Derived CD19/CD22-CAR TCells in B-Cell ALL | Recruiting | USA | 0 |
NCT05098613 | Phase I | CD19-22.BB.z CAR T cells | Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients | Recruiting | USA | 0 |
NCT03233854 | Phase I | Cyclophosphamide + Fludarabine CD19-22.BB.z CAR T cells NKTR-255 | CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies | Active, not recruiting | USA | 0 |
NCT06559189 | Phase I | CD19-22.BB.z CAR T cells | CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL | Recruiting | USA | 0 |
NCT03241940 | Phase I | Cyclophosphamide + Fludarabine CD19-22.BB.z CAR T cells | Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies | Recruiting | USA | 0 |